TARRYTOWN, N.Y. and CAMBRIDGE,
Mass., May 16, 2019
/PRNewswire/ --
New data at ASCO include more than double the patients
previously reported; median overall survival still not reached with
a median follow-up of up to 17 months
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi
today announced that positive updated data for Libtayo®
(cemiplimab-rwlc) in locally advanced and metastatic cutaneous
squamous cell carcinoma (CSCC) will be shared at the 2019 American
Society of Clinical Oncology (ASCO) Annual Meeting from
May 31 to June 4 in Chicago. Libtayo is a fully-human monoclonal
antibody targeting the immune checkpoint receptor PD-1 (programmed
cell death protein-1) and is the only treatment approved for
patients with metastatic CSCC or locally advanced CSCC who are not
candidates for curative surgery or curative radiation in the
U.S.
These data from the pivotal Phase 2 EMPOWER-CSCC-1 trial include
the primary analysis for the locally advanced CSCC group and
longer-term data from the metastatic CSCC group. Together, they
provide updated Libtayo efficacy and safety outcomes following its
approval by the U.S. Food and Drug Administration (FDA) in
September 2018 and will be shared
alongside two additional joint Regeneron-Sanofi abstracts on
CSCC.
"The data presented at this meeting offer longer-term
results in more than twice as many patients as initially reported
for the Phase 2 trial at ASCO last year, confirming how
Libtayo can lead to beneficial and significant treatment outcomes
for patients with advanced CSCC," said Israel Lowy, M.D., Ph.D., Head of Clinical and
Translational Sciences, Oncology at Regeneron. "The medical
community's rapid adoption of Libtayo since its approval last
September is a testament to its strong body of evidence and the
great unmet need in advanced CSCC."
Key data from EMPOWER-CSCC-1 include:
|
Locally Advanced
CSCC
(n=78a)
|
Metastatic
CSCC
(n=59b)
|
Median
follow-upc
|
9 months
(Range: 1 to 28
months)
|
17 months
(Range: 1 to 27
months)
|
Overall response
rated
(n; 95% confidence
interval [CI])
|
44%
(34; 32%,
55%)
|
49%
(29; 36%,
63%)
|
Complete response
rated
|
13% (10)
|
17% (10)
|
Partial response
rated
|
31% (24)
|
32% (19)
|
Median duration of
response (DOR)
|
Not yet
reached
|
Not yet
reached
|
Median observed time
to response
|
2 months
(Range: 2 to 9
months)
|
2 months
(Range: 2 to 9
months)
|
Durable disease
control rate
(DCR) of ≥16 weekse
|
63%
(95% CI: 51% to
74%)
|
63%
(95% CI: 49% to
75%)
|
Median progression
free survival
|
Not yet
reached
|
18 months
(95% CI: 7 months to
not evaluable)
|
Median overall
survival
|
Not yet
reached
|
Not yet
reached
|
a October
10, 2018 data cutoff
|
b
September 20, 2018 data cutoff
|
c
Excluding survival follow-up
|
d As
assessed by central review
|
e Durable DCR includes stable disease
or response
|
Among patients with locally advanced CSCC, the most common
adverse events (AEs) were fatigue (42%), diarrhea and pruritus
(both 27%) and nausea (22%). Grade 3 or higher immune-related AEs
occurred in 10% of patients; one patient died due to an unknown
cause assessed as treatment-related. Among patients with metastatic
CSCC, the most common AEs were diarrhea (29%), fatigue (25%) and
nausea (24%). Investigator-assessed Grade 3 or higher
immune-related AEs occurred in 14% of patients.
In addition to the EMPOWER-CSCC-1 data, Regeneron and Sanofi are
also sharing results from the largest retrospective data set of
patients with metastatic or locally advanced CSCC who were treated
with chemotherapy or an EGFR (epidermal growth factor receptor)
inhibitor but who did not receive anti-PD-1 or anti-PD-L1
therapy.
Regeneron and Sanofi joint presentations at ASCO include:
Poster Discussion and Poster Sessions
- Primary analysis of Phase 2 results of cemiplimab, a human
monoclonal anti-PD-1, in patients with locally advanced cutaneous
squamous cell carcinoma (Dr. Michael Migden; Saturday,
June 1; Poster Display: 1:15-4:15
PM; Poster Discussion: 4:30-6:00
PM)
- Phase 2 study of cemiplimab, a human monoclonal anti-PD-1,
in patients with metastatic cutaneous squamous cell carcinoma
(mCSCC; Group 1): 12 month follow-up (Dr. Alexander
Guminski; Monday, June 3; Poster Display: 1:15-4:15 PM)
Publication-Only Abstracts
- Treatment patterns and outcomes among patients with advanced
cutaneous squamous cell carcinoma in a U.S. community oncology
setting (Dr. C. Lance
Cowey; Publication Only)
- Patterns of major surgeries among patients diagnosed with
cutaneous squamous cell carcinoma (Chieh-I Chen;
Publication Only)
Libtayo is being jointly developed by Regeneron and Sanofi under
a global collaboration agreement. Libtayo was invented by Regeneron
using the company's proprietary VelocImmune®
technology that yields optimized fully-human antibodies.
About CSCC
CSCC is the second most common type of skin
cancer in the world, accounting for approximately 20% of all skin
cancers, and the number of newly diagnosed cases is expected to
rise substantially in many countries. Although CSCC has a good
prognosis when caught early, the cancer can prove especially
difficult to treat effectively when it is advanced, and patients
can experience reduced quality of life due to the impact of the
disease as it progresses. Advanced CSCC is the deadliest
non-melanoma skin cancer. While estimates vary, sources suggest
that 7,000 people in the U.S. die annually of advanced CSCC.
About Libtayo
Libtayo is approved in the U.S.,
Canada and Brazil, and under review by the European
Commission following a positive opinion for conditional approval by
the Committee for Medicinal Products for Human Use (CHMP). In the
U.S., Libtayo is approved for the treatment of patients with
metastatic CSCC or locally advanced CSCC who are not candidates for
curative surgery or curative radiation. The generic name for
Libtayo in the U.S. is cemiplimab-rwlc, with rwlc as the suffix
designated in accordance with Nonproprietary Naming of Biological
Products Guidance for Industry issued by the FDA.
Libtayo is also being investigated in potential registrational
trials in non-small cell lung cancer, basal cell carcinoma and
cervical cancer, along with additional trials in squamous cell
carcinoma of the head and neck, melanoma, colorectal cancer,
prostate cancer, multiple myeloma, Hodgkin's lymphoma and
non-Hodgkin's lymphoma. These trials are designed to investigate
Libtayo as monotherapy; in combination with conventional treatments
like chemotherapy; or in combination with other investigational
agents, including vaccines, oncolytic viruses and bispecific
antibodies, among others. These potential uses are investigational,
and their safety and efficacy have not been evaluated by any
regulatory authority.
IMPORTANT SAFETY INFORMATION AND INDICATION FOR U.S.
PATIENTS
What is the most important information I should know about
Libtayo?
Libtayo is a medicine that may treat a type of skin
cancer by working with your immune system. Libtayo can cause your
immune system to attack normal organs and tissues in any area of
your body and can affect the way they work. These problems can
sometimes become severe or life-threatening and can lead to death.
These problems may happen anytime during treatment or even after
your treatment has ended.
Call or see your healthcare provider right away if you
develop any symptoms of the following problems or these symptoms
get worse:
- Lung problems (pneumonitis). Signs and
symptoms of pneumonitis may include new or worsening cough,
shortness of breath, and chest pain.
- Intestinal problems (colitis) that can lead to tears or
holes in your intestine. Signs and symptoms of
colitis may include diarrhea (loose stools) or more frequent bowel
movements than usual; stools that are black, tarry, sticky or that
have blood or mucus; and severe stomach-area (abdomen) pain or
tenderness.
- Liver problems (hepatitis). Signs and
symptoms of hepatitis may include yellowing of your skin or the
whites of your eyes, severe nausea or vomiting, pain on the right
side of your stomach area (abdomen), drowsiness, dark urine (tea
colored), bleeding or bruising more easily than normal, and feeling
less hungry than usual.
- Hormone gland problems (especially the adrenal glands,
pituitary, thyroid and pancreas). Signs and symptoms that your
hormone glands are not working properly may include headaches that
will not go away or unusual headaches, rapid heartbeat, increased
sweating, extreme tiredness, weight gain or weight loss, dizziness
or fainting, feeling more hungry or thirsty than usual, hair loss,
feeling cold, constipation, deeper voice, very low blood pressure,
urinating more often than usual, nausea or vomiting, stomach-area
(abdomen) pain, and changes in mood or behavior, such as decreased
sex drive, irritability, or forgetfulness.
- Kidney problems, including nephritis and kidney failure.
Signs of these problems may include decrease in your amount of
urine, blood in your urine, swelling in your ankles, and loss of
appetite.
- Skin problems. Signs of these problems may include rash,
itching, skin blistering, and painful sores or ulcers in the mouth,
nose, throat, or genital area.
- Problems in other organs. Signs of these problems may
include headache, tiredness or weakness, sleepiness, changes in
heartbeat (such as beating fast, seeming to skip a beat, or a
pounding sensation), confusion, fever, muscle weakness, balance
problems, nausea, vomiting, stiff neck, memory problems, seizures
(encephalitis), swollen lymph nodes, rash or tender lumps on skin,
cough, shortness of breath, vision changes, or eye pain
(sarcoidosis), seeing or hearing things that are not there
(hallucinations), severe muscle weakness, low red blood cells
(anemia), bruises on the skin or bleeding, and changes in
eyesight.
- Rejection of a transplanted organ. Your doctor should
tell you what signs and symptoms you should report and monitor you,
depending on the type of organ transplant that you have had.
- Infusion (IV) reactions that can sometimes be severe
and life-threatening. Signs of these problems may include
chills or shaking, itching or rash, flushing, shortness of breath
or wheezing, dizziness, fever, feeling of passing out, back or neck
pain, and facial swelling.
Getting medical treatment right away may help keep these
problems from becoming more serious.
Your healthcare provider will check you for these problems
during your treatment with Libtayo. Your healthcare provider may
treat you with corticosteroid or hormone replacement medicines.
Your healthcare provider may delay or completely stop treatment if
you have severe side effects.
Before you receive Libtayo, tell your healthcare
provider about all your medical conditions, including if
you:
- have immune system problems such as Crohn's disease, ulcerative
colitis, or lupus;
- have had an organ transplant;
- have lung or breathing problems;
- have liver or kidney problems;
- have diabetes;
- are pregnant or plan to become pregnant; Libtayo can harm your
unborn baby.
Females who are able to become pregnant:
-
- Your healthcare provider will give you a pregnancy test before
you start treatment.
- You should use an effective method of birth control during your
treatment and for at least 4 months after your last dose of
Libtayo. Talk with your healthcare provider about birth control
methods that you can use during this time.
- Tell your healthcare provider right away if you become pregnant
or think you may be pregnant during treatment with Libtayo.
- are breastfeeding or plan to breastfeed. It is not known if
Libtayo passes into your breast milk. Do not breastfeed during
treatment and for at least 4 months after the last dose of
Libtayo.
Tell your healthcare provider about all the medicines you
take, including prescription and
over-the-counter medicines, vitamins, and herbal supplements.
The most common side effects of Libtayo include tiredness, rash,
and diarrhea. These are not all the possible side effects of
Libtayo. Call your doctor for medical advice about side effects.
You may report side effects to FDA at 1-800-FDA-1088. You may also
report side effects to Regeneron Pharmaceuticals and Sanofi at
1-877-542-8296.
Please see accompanying full Prescribing Information,
including Medication Guide.
What is Libtayo?
Libtayo is a prescription medicine used to treat people with a
type of skin cancer called cutaneous squamous cell carcinoma (CSCC)
that has spread or cannot be cured by surgery or radiation.
It is not known if Libtayo is safe and effective in
children.
About Regeneron Pharmaceuticals, Inc.
Regeneron
(NASDAQ: REGN) is a leading biotechnology company that invents
life-transforming medicines for people with serious diseases.
Founded and led for 30 years by physician-scientists, our unique
ability to repeatedly and consistently translate science into
medicine has led to seven FDA-approved treatments and numerous
product candidates in development, all of which were homegrown in
our laboratories. Our medicines and pipeline are designed to help
patients with eye diseases, allergic and inflammatory diseases,
cancer, cardiovascular and metabolic diseases, neuromuscular
diseases, infectious diseases and rare diseases.
Regeneron is accelerating and improving the traditional drug
development process through our proprietary
VelociSuite® technologies, such as
VelocImmune® which produces optimized fully-human
antibodies, and ambitious research initiatives such as the
Regeneron Genetics Center, which is conducting one of the largest
genetics sequencing efforts in the world.
For additional information about the company, please visit
www.regeneron.com or follow @Regeneron on Twitter.
About Sanofi
Sanofi is dedicated to supporting people
through their health challenges. We are a global biopharmaceutical
company focused on human health. We prevent illness with vaccines,
provide innovative treatments to fight pain and ease suffering. We
stand by the few who suffer from rare diseases and the millions
with long-term chronic conditions.
With more than 100,000 people in 100 countries, Sanofi is
transforming scientific innovation into healthcare solutions around
the globe.
Sanofi, Empowering Life
Regeneron Forward-Looking Statements and Use of Digital
Media
This press release includes forward-looking
statements that involve risks and uncertainties relating to future
events and the future performance of Regeneron Pharmaceuticals,
Inc. ("Regeneron" or the "Company"), and actual events or results
may differ materially from these forward-looking
statements. Words such as "anticipate," "expect," "intend,"
"plan," "believe," "seek," "estimate," variations of such words,
and similar expressions are intended to identify such
forward-looking statements, although not all forward-looking
statements contain these identifying words. These statements
concern, and these risks and uncertainties include, among others,
the nature, timing, and possible success and therapeutic
applications of Regeneron's products, product candidates, and
research and clinical programs now underway or planned, including
without limitation Libtayo® (cemiplimab) Injection;
uncertainty of market acceptance and commercial success of
Regeneron's products (such as Libtayo) and product candidates and
the impact of studies (whether conducted by Regeneron or others and
whether mandated or voluntary), including the EMPOWER-CSCC-1 trial
discussed in this press release, on the commercial success of
Regeneron's products and product candidates; the likelihood,
timing, and scope of possible regulatory approval and commercial
launch of Regeneron's late-stage product candidates and new
indications for marketed products, including any possible
regulatory approval of Libtayo for non-small cell lung cancer,
basal cell carcinoma, cervical cancer, squamous cell carcinoma of
the head and neck, melanoma, colorectal cancer, prostate cancer,
multiple myeloma, Hodgkin's lymphoma, and non-Hodgkin's lymphoma
(as monotherapy or in combination with other conventional
treatments or other investigational agents); unforeseen safety
issues resulting from the administration of products and product
candidates in patients, including serious complications or side
effects in connection with the use of Regeneron's product
candidates (such as Libtayo) in clinical trials; the extent to
which the results from the research and development programs
conducted by Regeneron or its collaborators may be replicated in
other studies and lead to therapeutic applications; ongoing
regulatory obligations and oversight impacting Regeneron's marketed
products (such as Libtayo), research and clinical programs, and
business, including those relating to patient privacy;
determinations by regulatory and administrative governmental
authorities which may delay or restrict Regeneron's ability to
continue to develop or commercialize Regeneron's products and
product candidates, including without limitation Libtayo; competing
drugs and product candidates that may be superior to Regeneron's
products and product candidates; the ability of Regeneron to
manufacture and manage supply chains for multiple products and
product candidates; the ability of Regeneron's collaborators,
suppliers, or other third parties (as applicable) to perform
manufacturing, filling, finishing, packaging, labeling,
distribution, and other steps related to Regeneron's products and
product candidates; the availability and extent of reimbursement of
the Company's products (such as Libtayo) from third-party payers,
including private payer healthcare and insurance programs, health
maintenance organizations, pharmacy benefit management companies,
and government programs such as Medicare and Medicaid; coverage and
reimbursement determinations by such payers and new policies and
procedures adopted by such payers; unanticipated expenses; the
costs of developing, producing, and selling products; the ability
of Regeneron to meet any of its financial projections or guidance
and changes to the assumptions underlying those projections or
guidance; risks associated with intellectual property of other
parties and pending or future litigation relating thereto,
including without limitation the patent litigation and other
related proceedings relating to EYLEA® (aflibercept)
Injection, Dupixent® (dupilumab) Injection, and
Praluent® (alirocumab) Injection, the ultimate outcome
of any such proceedings, and the impact any of the foregoing may
have on Regeneron's business, prospects, operating results, and
financial condition; and the potential for any license or
collaboration agreement, including Regeneron's agreements with
Sanofi, Bayer, and Teva Pharmaceutical Industries Ltd. (or their
respective affiliated companies, as applicable), to be cancelled or
terminated without any further product success. A more complete
description of these and other material risks can be found in
Regeneron's filings with the U.S. Securities and Exchange
Commission, including its Form 10-K for the year ended December 31, 2018 and its Form 10-Q for the
quarterly period ended March 31,
2019. Any forward-looking statements are made based on
management's current beliefs and judgment, and the reader is
cautioned not to rely on any forward-looking statements made by
Regeneron. Regeneron does not undertake any obligation to
update publicly any forward-looking statement, including without
limitation any financial projection or guidance, whether as a
result of new information, future events, or otherwise.
Regeneron uses its media and investor relations website and
social media outlets to publish important information about the
Company, including information that may be deemed material to
investors. Financial and other information about Regeneron is
routinely posted and is accessible on Regeneron's media and
investor relations website
(http://newsroom.regeneron.com) and its Twitter feed
(http://twitter.com/regeneron).
Sanofi Forward-Looking Statements
This press
release contains forward-looking statements as defined in the
Private Securities Litigation Reform Act of 1995, as amended.
Forward-looking statements are statements that are not historical
facts. These statements include projections and estimates and their
underlying assumptions, statements regarding plans, objectives,
intentions and expectations with respect to future financial
results, events, operations, services, product development and
potential, and statements regarding future performance.
Forward-looking statements are generally identified by the words
"expects", "anticipates", "believes", "intends", "estimates",
"plans" and similar expressions. Although Sanofi's management
believes that the expectations reflected in such forward-looking
statements are reasonable, investors are cautioned that
forward-looking information and statements are subject to various
risks and uncertainties, many of which are difficult to predict and
generally beyond the control of Sanofi, that could cause actual
results and developments to differ materially from those expressed
in, or implied or projected by, the forward-looking information and
statements. These risks and uncertainties include among other
things, the uncertainties inherent in research and development,
future clinical data and analysis, including post marketing,
decisions by regulatory authorities, such as the FDA or the EMA,
regarding whether and when to approve any drug, device or
biological application that may be filed for any such product
candidates as well as their decisions regarding labelling and other
matters that could affect the availability or commercial potential
of such product candidates, the absence of guarantee that the
product candidates if approved will be commercially successful, the
future approval and commercial success of therapeutic alternatives,
Sanofi's ability to benefit from external growth opportunities
and/or obtain regulatory clearances, risks associated with
intellectual property and any related pending or future litigation
and the ultimate outcome of such litigation, trends in
exchange rates and prevailing interest rates, volatile economic
conditions, the impact of cost containment initiatives and
subsequent changes thereto, the average number of shares
outstanding as well as those discussed or identified in the public
filings with the SEC and the AMF made by Sanofi, including those
listed under "Risk Factors" and "Cautionary Statement Regarding
Forward-Looking Statements" in Sanofi's annual report on Form 20-F
for the year ended December 31, 2018.
Other than as required by applicable law, Sanofi does not undertake
any obligation to update or revise any forward-looking information
or statements.
Regeneron
Contacts:
|
Sanofi
Contacts:
|
Media
Relations
Daren Kwok
Tel: +1 (914)
847-1328
daren.kwok@regeneron.com
Investor
Relations
Mark
Hudson
Tel: +1 (914)
847-3482
Mark.Hudson@regeneron.com
|
Media
Relations
Ashleigh
Koss
Tel: +1 (908)
981-8745
ashleigh.koss@sanofi.com
Investor
Relations
George
Grofik
Tel.: +33 (0)1 53 77
45 45
ir@sanofi.com
|
View original
content:http://www.prnewswire.com/news-releases/updated-libtayo-cemiplimab-rwlc-results-reinforce-durable-and-substantial-response-rates-in-advanced-cutaneous-squamous-cell-carcinoma-300851556.html
SOURCE Regeneron Pharmaceuticals, Inc.